Pergola PE, Rosenbaum DP, Yang Y, et al. - Since there is lack of knowledge regarding safety and effectiveness of integrating two therapies with different mechanisms of action—tenapanor, an inhibitor of paracellular phosphate absorption, and phosphate binders—for hyperphosphatemia management in maintenance dialysis patients, so, researchers addressed this topic in this double-blind phase 3 trial wherein 236 patients receiving maintenance dialysis with hyperphosphatemia despite taking phosphate binder therapy were randomized to receive oral tenapanor 30 mg twice daily or placebo for 4 weeks. It was found that improved control of hyperphosphatemia was conferred by a dual-mechanism treatment using both tenapanor and phosphate binders, vs phosphate binders alone, among participants receiving maintenance dialysis.